Positive Phase IIb/III study data for filgotinib in the treatment of moderately to severely active ulcerative colitis

The SELECTION study looked at two doses of the JAK inhibitor. The higher dose (200mg) was associated with clinical remission at week 10 in 26.1% of biologic-naïve patients (v 15.3% placebo) and in 11.5% of biologic-experienced patients (4.2% placebo) (no p values reported).

SPS commentary:

In the maintenance period, both doses of filgotinib achieved the primary endpoint, with clinical remission at week 58 achieved in 37.2% of biologic-naïve and biologic-experienced patients receiving filgotinib 200mg (v 11.2% placebo) and in 23.8% of those receiving 100mg (v 13.5% placebo).

Filgotinib is an investigational selective JAK inhibitor currently under regulatory review for rheumatoid arthritis, and also being studied in the treatment of Crohn’s disease and psoriatic arthritis

Biospace Inc.